Overexpression of methyltransferase‐like 3 and 14 in oral squamous cell carcinoma

Wu, Shuangjiang; Makeudom, Anupong; Sun, Xingwang; Li, Xiabin; Xu, Duo; Sastraruji, Thanapat; Lumbikananda, Narong; Buranaphatthana, Worakanya; Krisanaprakornkit, Suttichai

doi:10.1111/jop.13256

Cited by 10 publications

(13 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…192 , 193 Furthermore, the combined effect of METTL3 and METTL14 on oral squamous cell carcinoma was studied. 194 Moreover, in addition to the several types of RNA modifications discovered to date, there must be other RNA modifications that have not been discovered. Therefore, developing more advanced and accurate tools for determining RNA modifications is crucial to explore further the role of RNA modifications at different stages of tumor development and discover new RNA modifications.…”

Section: Discussionmentioning

confidence: 99%

RNA Modifications Meet Tumors

Yang¹,

Zhang²,

Xia³

et al. 2022

CMAR

View full text Add to dashboard Cite

RNA modifications occur through the whole process of gene expression regulation, including transcription, translation, and post-translational processes. They are closely associated with gene expression, RNA stability, and cell cycle. RNA modifications in tumor cells play a vital role in tumor development and metastasis, changes in the tumor microenvironment, drug resistance in tumors, construction of tumor cell-cell “internet”, etc. Several types of RNA modifications have been identified to date and have various effects on the biological characteristics of different tumors. In this review, we discussed the function of RNA modifications, including N 6 -methyladenine (m 6 A), 5-methylcytosine (m 5 C), N 7 -methyladenosine (m 7 G), N 1 -methyladenosine (m 1 A), pseudouridine (Ψ), and adenosine-to-inosine (A-to-I), in the microenvironment and therapy of solid and liquid tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

RNA Modifications Meet Tumors

Yang¹,

Zhang²,

Xia³

et al. 2022

CMAR

View full text Add to dashboard Cite

show abstract

“…The relationship between METTL3 expression levels and prognosis has been examined in different types of human cancer (47)(48)(49)(50). METTL3 was shown to be downregulated in glioma tissues, and the downregulation of METTL3 was shown to stimulate the malignant development of glioma (51).…”

Section: Discussionmentioning

confidence: 99%

Methyltransferase-like 3 upregulation is involved in the chemoresistance of non-small cell lung cancer

Shi¹,

Gong²,

Zhuo³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background: Treatments for non-small cell lung cancer (NSCLC) have improved tremendously, but therapeutic resistance is a common and major clinical challenge in treatment. Methyltransferase-like 3 (METTL3) is a ribonucleic acid (RNA) methyltransferase that has crucial functions in the development and progression of cancers, including drug resistance, by regulating N6-methyladenosine (m 6 A) modification.However, the role of METTL3 in the progression and drug resistance of NSCLC is poorly understood. Methods:The expression levels of METTL3 and AKT serine/threonine kinase 1 (AKT1) in NSCLC tissues were detected using quantitative real-time PCR (RT-qPCR), Western blots, and immunohistochemical assays. The m 6 A levels of AKT1 messenger RNA (mRNA) in NSCLC tissues were detected using m 6 A methylated RNA immunoprecipitation-quantitative polymerase chain reaction. Results:The expression levels of METTL3 and the AKT1 protein were significantly increased in NSCLC tissues, and m6A expression levels of AKT1 mRNA were dramatically upregulated in NSCLC tissues. Additionally, METTL3, AKT1 protein, and m 6 A levels of AKT1 mRNA were overexpressed in chemoresistant NSCLC samples, and high expression levels of METTL3 and AKT1 were correlated with poor patient survival, especially in chemoresistant NSCLC patients. Further, AKT1 protein expression and m 6 A levels of AKT1 mRNA were positively correlated with METTL3 expression, and AKT1 protein expression was positively correlated with m 6 A levels of AKT1 mRNA. Moreover, METTL3 and AKT1 protein expression levels were significantly associated with cisplatin susceptibility, tumor, node, metastasis stage, and lymph node metastasis.Conclusions: Taken together, our results indicate that METTL3 contributes to the progression and chemoresistance of NSCLC by promoting AKT1 protein expression through regulating AKT1 mRNA m6A levels, and may provide an efficient therapeutic intervention target for overcoming chemoresistance in NSCLC.

show abstract

“…[14][15][16][17] These studies suggested that METTL3 could promote the proliferation and migration of OSCC cells in vitro and tumor growth in vivo. [14][15][16][17] However, there are limited data on the role of METTL3 in oral precancerous lesions, especially in oral epithelial dysplasia (OED).…”

Section: Introductionmentioning

confidence: 94%

The Expression of Methyltransferase-Like 3 in Oral Precancerous Lesions and Oral Squamous Cell Carcinoma

Udompatanakorn

Taebunpakul

2022

Eur J Dent

View full text Add to dashboard Cite

Objective N6-methyladenosine is the most frequent mRNA modification in eukaryotic cells. It is catalyzed by the methyltransferase complex, methyltransferase-like 3 (METTL3). Previous studies have revealed that METTL3 plays a role in various cancers. However, there is limited information about the roles of METTL3 in oral epithelial dysplasia (OED). This study determined METTL3 expression in normal oral mucosa (NOM), OED, and oral squamous cell carcinoma (OSCC) by immunohistochemistry. Materials and Methods Twenty formalin-fixed paraffin embedded specimens each of NOM, OED, and OSCC were included. The expression pattern, the number of positive cells, the staining intensity, and the histochemical score (H-score) of METTL3 were investigated. Statistical Analysis The data were analyzed by using one-way analysis of variance, chi-squared test, and a Kruskal–Wallis test. A p-value < 0.05 indicated statistically significant. Results The METTL3 expression in NOM was observed in the basal, parabasal, and lower layers of epithelium. In low-grade OED, METTL3 was expressed in the lower epithelial layers and partially presented in the spinous layer. However, in high-grade OED, METTL3 expression was observed in the lower layers, spinous layers, and upper layers of dysplastic epithelium. For OSCC, METTL3 immunostaining was presented in both the peripheral and central cells of the tumor islands. All NOM samples showed weak-to-moderate METTL3 staining intensity, while the moderate-to-strong METTL3 staining intensity was observed in 95% of both OED and OSCC specimens (p < 0.05). The percentage of METTL3 positive cells and H-score was highest in OSCC, followed by OED and NOM, respectively (p < 0.05). Interestingly, H-score was greater in high-grade OED (209.8 ± 18.61) when compared with low-grade OED (162.1 ± 38.93) (p < 0.05). Conclusion METTL3 expression in OED and OSCC was more outstanding than in NOM, suggesting possible roles for OED and OSCC pathogenesis. Additionally, METTL3 expression may be an indicator for OED progression to OSCC.

show abstract

Overexpression of methyltransferase‐like 3 and 14 in oral squamous cell carcinoma

Cited by 10 publications

References 24 publications

RNA Modifications Meet Tumors

RNA Modifications Meet Tumors

Methyltransferase-like 3 upregulation is involved in the chemoresistance of non-small cell lung cancer

The Expression of Methyltransferase-Like 3 in Oral Precancerous Lesions and Oral Squamous Cell Carcinoma

Contact Info

Product

Resources

About